April 13, 2021

Koenraad Wiedhaup and David Schenkein talk about Leyden Labs' approach to pandemic preparedness

In this video interview, Leyden Labs’ CEO Koenraad Wiedhaup sat down with GV General Partner and member of our board of directors, David Schenkein, M.D., to discuss the company becoming a part of GV’s life science portfolio and the completion of our €40 Million Series A financing. The two talk about the company’s plans for funding, including advancing our platform, developing our portfolio of products for respiratory viruses and building out our fantastic team. Other highlights include Leyden Labs’ birth story, insight into our proactive approach of targeting viral families and our intranasal products potential to give people the freedom to administer protection themselves.

Visit GV's news page to read the full article.



Media inquiries

Residing Address

Paasheuvelweg 25 – D5
1105 BP Amsterdam
The Netherlands

Registered Address

Keizersgracht 290 A
1016 EW Amsterdam
The Netherlands



Stay updated

© Leyden Labs, 2021  |  Privacy Policy  |  Design by Ape to Zebra

Back to top Arrow